Be a Smart Investor
Monday, November 11, 2019
FDA Rejects Lipocine's TLANDO Yet Again
The FDA has turned down Lipocine Inc.'s (LPCN) TLANDO, an oral testosterone product candidate for testosterone replacement therapy in adult males for hypogonadism, yet again.
from RTT - Biotech https://ift.tt/2qFnBx6
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment